Introduction {#s1}
============

How embryonic pluripotent cells can maintain an uncommitted state as well as an unrestricted potential for multi-lineage commitment is a key and unresolved question in developmental and stem cell biology. Therefore, studying in vivo the links between factors that oppositely regulate pluripotency should help to better understand the transitory nature of this state during embryogenesis and its resumption in several human diseases. In mammals, epiblast cells of the developing blastula embryo appear to transit through a series of pluripotent states until gastrulation, which signs the global extinction of pluripotency and the rise of cell competence to somatically commit ([@bib17]; [@bib1]). In amphibians, cells of the blastula animal hemisphere are somatically pluripotent, and their broad potential is globally lost at gastrulation ([@bib33]). Studies in vivo have been useful to characterize the core regulatory network of pluripotency, and to reveal its degree of conservation and plasticity during vertebrate evolution ([@bib1]; [@bib17]; [@bib25]; [@bib31]; [@bib3]; [@bib2]). In vertebrates, the pluripotency regulatory network is centered on the Pou-V class of transcription factors (also referred as Oct4). Pou-V members *Pou5f3* and *Pou5f1* share functional homology in regulating the uncommitted state of progenitor cells ([@bib21]) and in reprogramming somatic cells to induced-Pluripotent Stem Cells (iPSCs) ([@bib38]; [@bib37]). Nanog has been discovered as a key component of pluripotency networks in both mouse embryonic stem cells (mESC) and pre-implantation epiblast ([@bib17]; [@bib1]). Nonetheless, phylogenetic, biochemical and functional analyses suggest that the role of Nanog in pluripotency is not conserved in all vertebrates, as the *Nanog* gene is absent in the *Xenopus* genus ([@bib32]) and teleostean *Nanog* does not support pluripotency during development ([@bib4]; [@bib32]). Recent analyses on *Xenopus* and zebrafish embryos suggest that Ventx transcription factors, belonging to the same NK family as Nanog ([@bib32]), act as guardians of pluripotency during embryogenesis ([@bib31]; [@bib40]). Ventx factors integrate the pluripotency network by coordinating and maintaining the activity of Pou-V factors ([@bib31]; [@bib40]; [@bib5]), and by regulating cell response to TGF-β/Smad pathways ([@bib41]; [@bib5]). However, how the pluripotency network evolves to authorize the expression of lineage-specific genes in lower vertebrates is poorly understood. Pluripotency is maintained by a complex gene regulatory network associated with a specific epigenetic state both in vitro and in vivo ([@bib1]). Several studies revealed the importance of transcriptional and epigenetic silencing of pluripotency-related genes during the process of cell commitment, which ultimately allows the transcriptional activation of lineage-specific genes ([@bib17]). Based on in vitro studies, the regulation of pluripotency factor stability and degradation ([@bib18]; [@bib34]), as well as the asymmetric distribution of cytoplasmic and membrane-bound determinants during cell division ([@bib16]), are also expected to significantly contribute to pluripotency destabilization. However, whether such mechanisms are important during vertebrate embryogenesis remains to be addressed. Studies in mammalian embryos have suggested that MEK1 (*Map2k1*), an upstream component of the mitogen activated protein kinase (MAPK) pathway, could represent an intrinsic determinant of the ephemeral and transitory nature of the pluripotency state in vivo ([@bib2]; [@bib1]). Further support to this idea comes from the reported stabilization in a pluripotent state of mammalian ESCs in vitro by media that include inhibitors of MEK1 activity ([@bib1]; [@bib17]; [@bib39]). MEK1 activity can negatively regulate both the expression in vivo ([@bib2]; [@bib1]) and the stability in vitro of Nanog and Pou5f1 proteins ([@bib18]; [@bib34]). The *Xenopus* embryo also represents an attractive model to address how MEK1 controls pluripotency exit in vivo, as the importance of the MAPK pathway for the competence of embryonic cells to differentiate has long been known ([@bib20]). Activation of the MAPK ERK1, resulting from phosphorylation by MEK1, is known to occur at early blastula stages, primarily in the pluripotent cells of the animal and marginal zones ([@bib12]). Multiple studies revealed that FGF-mediated ERK1 activation is necessary for the competence of animal blastula cells to respond to mesoderm and neural inducers ([@bib11]; [@bib13]). However, the existence of a direct link between the MAPK pathway and pluripotency during *Xenopus* development has never been tested. In this study, we reveal that MEK1 is required for embryonic cell competence to respond to differentiation cues, acting against the expression, distribution and stability of the pluripotency regulator Ventx2.

Results {#s2}
=======

MEK1 is required for cell competence to differentiate {#s2-1}
-----------------------------------------------------

To examine the role of MEK1 in *Xenopus* embryos, we depleted it through injection of morpholino antisense oligonucleotides (MOs). We designed two independent MOs, in the 5\'UTR (Mk-MO), and at the ATG (Mk-MO ATG), which both inhibited MEK1 translation and antagonized development ([Figure 1A--D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1--1A](#fig1s1){ref-type="fig"}). As Mk-MO proved more efficient, we used it for most experiments in this study, unless stated otherwise. Mk-MO did not up-regulate *p53* expression ([Figure 1---figure supplement 1--1B](#fig1s1){ref-type="fig"}), unlike the non-specific response triggered by some MOs in zebrafish embryos ([@bib29]). Importantly, a wild-type form of MEK1 from hamster efficiently rescued mesoderm and neural specification, as well as early morphogenesis, in Mk morphant embryos, indicating that MEK1 knockdown was specific ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1--1C and D](#fig1s1){ref-type="fig"}). We found that MEK1 activity was required for the expression of multiple neural and non-neural ectoderm, as well as mesoderm markers ([Figure 1---figure supplement 1--2A and B](#fig1s2){ref-type="fig"}). In contrast, MEK1 activity was found to be dispensable for the expression of endoderm markers and of immediate-early targets of the BMP and Nodal pathways ([Figure 1---figure supplement 1--2C and D](#fig1s2){ref-type="fig"}). Interestingly, the expression of the epidermal markers *dlx3*, *gata2* and *xk81a1* was reduced in MEK1 morphants, despite the maintained expression of the epidermal inducer *bmp4*. These results suggested that MEK1 was broadly required for multi-lineage commitment of pluripotent cells of the animal hemisphere. To further test this possibility, we examined the differentiation potential of embryonic cells depleted of MEK1 in response to exogenous inducers. Consistent with our hypothesis, recombinant BMP4, NODAL, and NOGGIN proteins induced efficient expression of epidermal, mesodermal and neural markers, respectively, in wild-type but not in MEK1-depleted cells ([Figure 2A](#fig2){ref-type="fig"}). Likewise, BMP signaling inhibition, obtained by injection of dominant-negative Smad5 ([@bib23]), caused neural induction in wild-type embryos, but not in Mk-MO ATG morphants ([Figure 2---figure supplement 2--1](#fig2s1){ref-type="fig"}). To directly assess the importance of MEK1 in the competence of pluripotent cells to respond to inducers, we exposed explanted animal ectoderm to the soluble factors described above. Whereas multiple epidermal, neural, mesodermal and endodermal markers were induced by BMP4, NOGGIN, low and high doses of NODAL, respectively, these responses were all abolished in the presence of Mk-MO ([Figure 2B](#fig2){ref-type="fig"}). The impaired ability of MEK1-deficient cells to engage into differentiation could be linked to mis-regulation of pluripotency genes. RT-qPCR analysis on early gastrula embryos revealed that the expression of *pou5f3.1* (*oct91*), *pou5f3.2* (*oct25*), *ventx1* and *ventx2* was significantly up-regulated in MEK1-depleted embryos, whereas no detectable effect was measured on *sox3* and *cdh1* (E-cadherin) ([Figure 2B](#fig2){ref-type="fig"})([Figure 2C](#fig2){ref-type="fig"}). *ventx2* and *pou5f3.2* are initially expressed throughout the pluripotent animal hemisphere and are restricted to non-neural ectoderm and floor plate at late gastrulation, respectively, reflecting the progressive engagement of embryonic cells into differentiation. In contrast, these two genes remained ubiquitously expressed in MEK1 morphants at late gastrula stage ([Figure 2D](#fig2){ref-type="fig"}). Likewise, targeted injection of Mk-MO in dorsal or ventral ectoderm confirmed that *pou5f3.2* and *ventx2* expression failed to be silenced, even when morphogenesis was not altered ([Figure 2---figure supplement 2--2A](#fig2s2){ref-type="fig"}). Strikingly, the maintenance of *pou5f3.2* expression in MEK1 morphants was still visible at mid-neurula stage ([Figure 2---figure supplement 2--2B](#fig2s2){ref-type="fig"}). Furthermore, gene expression analysis of MEK1-depleted animal ectoderm explants at the end of gastrulation revealed a significantly higher expression of *pou5f3.2* and *ventx2* with a concomitant reduction of the lineage-restricted markers *xk81a1*, *itln1* and *α-tub* ([Figure 2---figure supplement 2--2C](#fig2s2){ref-type="fig"}). Taken together, these data suggested that embryonic cells need MEK1 activity to exit pluripotency and engage into lineage-specific programs.10.7554/eLife.21526.002Figure 1.MEK1 depletion impairs embryonic development.(**A**) Mk-MO and Mk-MO ATG were designed to target MEK1 translation. Western blot analysis of blastula stage nine embryos injected with 25 ng per blastomere of either MO at the 4 cell stage revealed reduced MEK1 translation. α-Tubulin was used as a loading control. Control embryos were uninjected. The histogram shows the normalized intensity of MEK1 signals relative to control. (**B**) Embryos were injected as in (**A**) and morphology was analyzed at tailbud stage. (**C**) Embryos injected as in (**A**) were stained with *Sox2* probe to highlight defective axis formation and neural tissue differentiation. (**D**) Embryos were injected at the 2 cell stage with 25 ng Mk-MO per cell, and at the 4- cell stage with 400 pg of mammalian MEK1 (Mk) RNA per cell and processed for WISH analysis at late gastrula stage 13 with *t/bra* probe to highlight the mesoderm (dorso-vegetal view) and with *sox2* to highlight the neurectoderm (dorsal view). In C and D, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.002](10.7554/eLife.21526.002)10.7554/eLife.21526.003Figure 1---figure supplement 1.MEK1 depletion by morpholinos.(**A**) Four-cell embryos were injected in each blastomere with 50 pg GFP‐CAAX mRNA with or without 25 ng Mk-MO, fixed at blastula stage 9, cryosectioned and stained with anti-phospho-MEK1 antibody. The pMEK1 signal was severely reduced or lost in cells injected with Mk-MO. (**B**) Four-cell embryos were injected in each cell with 25 ng Mk-MO, collected at early gastrula stage 10.5 and processed for RT-qPCR to quantify *p53* expression levels. Mk‐MO did not induce *p53* expression. (**C**) Two-cell embryos were injected twice with 25 ng Mk-MO in each blastomere, followed by injection at 4 cell stage of hamster MEK1 mRNA (Mk; 400 pg per blastomere). In order to score progress through gastrulation pictures were taken from live stage 13 gastrula embryos (vegetal view). (**D**) Blastopore closure was scored by calculating the ratio of blastopore diameter of injected embryos to the mean of blastopore diameter of uninjected control embryos. Bars represent maximum and minimum values, and lines represent the mean. The number of embryos analyzed in each condition is displayed on the graph. For statistical analysis, samples were compared by Mann-Whitney test (99% confidence intervals were applied; \*\*\*p≤0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.21526.003](10.7554/eLife.21526.003)10.7554/eLife.21526.004Figure 1---figure supplement 1---source data 1.Values of blastopore closure ratios.Details are shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and Materials and methods.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.004](10.7554/eLife.21526.004)10.7554/eLife.21526.005Figure 1---figure supplement 2.Gene expression analysis of MEK1-depleted gastrula embryos.(**A--D**) Four-cell embryos were injected in each blastomere with 25 ng Mk-MO, collected at early gastrula stage 10.5 and processed for RT-qPCR to quantify changes in the expression levels of pro-differentiation markers (**A**), or changes in the expression levels of BMPs (Smad1/5/8) and Activin/Nodal (Smad2/3) signaling targets (**C**). For all qPCR graphs, error bars represent s.e.m. values of four independent experiments with two technical duplicates. For statistical analyses, samples from injected embryos were compared with samples from uninjected control embryos by Unpaired Student's t-test. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0001. (**B**,**D**) Some embryos from the same experiment were processed for WISH with the indicated probes. Note that embryos stained for *xk81a1* (epidermis) were injected with 25 ng Mk-MO in one ventral animal blastomere at 16-cell stage and collected at late gastrula stage 13. In B and D, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.005](10.7554/eLife.21526.005)10.7554/eLife.21526.006Figure 2.MEK1 depletion affects cell competence to exit pluripotency and enter into differentiation.(**A**) Sixteen-cell embryos were injected in one animal blastomere with 25 ng Mk-MO ATG and 2.5 ng FLDX. Next, these embryos were injected at blastula stage 8.5 with recombinant BMP4 (2 ng), NODAL (10 ng), or NOGGIN (36 ng) proteins into the blastocoele, collected at early gastrula stage 10.5, and processed for WISH with *xk81a1* (epidermis, animal view), *t/bra* (mesoderm, lateral view), and *sox2* (neural tissue, dorsal view). FLDX (orange staining) was used to trace Mk-MO injected cells (white arrows). (**B**) Four-cell embryos were injected with 25 ng Mk-MO per blastomere, animal caps were explanted at blastula stage 8.5 and cultured in the presence of 20 ng/ml BMP4, 100 ng/ml NOGGIN, 20 ng/ml NODAL (low), or 200 ng/ml NODAL (high) until late gastrula stage 13, and processed for RT-qPCR. (**C**) Four-cell embryos were injected with 25 ng Mk-MO per blastomere, collected at stage 10.5 and processed for RT-qPCR. (**D**) Embryos injected as in (**C**) were processed for WISH analysis at late gastrula stage 13 with *pou5f3.2* (*oct25*) and *ventx2* probes. a: animal view; v: ventral view; l: lateral view; d: dorsal view. For all qPCR graphs, error bars represent s.e.m. values of four independent experiments with two technical duplicates. For statistical analyses, samples were compared with the respective control by Unpaired Student's t-test. \*p\<0.05, \*\*p\<0.005. \*\*\*p\<0.0001. In A and D, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.006](10.7554/eLife.21526.006)10.7554/eLife.21526.007Figure 2---figure supplement 1.Neural induction in vivo depends on MEK1 activity.Sixteen-cell embryos were injected in one ventral-animal blastomere with 3 ng of dominant-negative Smad5 (Smad5sbn) mRNA and 25 ng Mk-MO ATG, as indicated. Embryos were fixed at late gastrula stage 13, and processed for WISH with the indicated probes. The number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated. Lateral views.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.007](10.7554/eLife.21526.007)10.7554/eLife.21526.008Figure 2---figure supplement 2.MEK1 is required to inhibit the expression of the pluripotency genes *pou5f3.2* and *ventx2*.(**A**) Embryos injected with 25 ng Mk-MO at 16-cell stage in one animal dorsal blastomere were grown until late gastrulation stage 13 and processed for WISH with *pou5f3.2* and *ventx2* probes. (**B**) Embryos injected with 25 ng Mk-MO at 16 cell stage in one animal ventral blastomere were grown until mid-neurula stage 18 and processed for WISH with *pou5f3.2* probe. (**C**) Four-cell embryos were injected in each blastomere with 25 ng Mk-MO and grown until blastula stage 9, when animal caps were isolated, cultured in vitro until late gastrula stage 13 and then processed for RT-qPCR. In A and B, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.008](10.7554/eLife.21526.008)

MEK1 regulates the sub-cellular distribution and clearance of Ventx2 {#s2-2}
--------------------------------------------------------------------

The above results raised the possibility that an elevated activity of pluripotency factors may promote resistance to differentiation. In *Xenopus*, Ventx2 is involved in the active repression of precocious differentiation and helps to maintain pluripotency ([@bib31]). Consistently, it was shown that Ventx2 undergoes ubiquitin-mediated degradation in the early gastrula ([@bib41]), which coincides with the global loss of pluripotency ([@bib33]). Ventx2 proteolysis involves a PEST-destruction motif in its N-terminus, which is regulated by phosphorylation by uncharacterized signaling pathways ([@bib41]). Noteworthy, this PEST domain is conserved in the Ventx family ([Supplementary file 1](#SD3-data){ref-type="supplementary-material"})([Supplementary file 4](#SD6-data){ref-type="supplementary-material"}), and one of the two functional serines in the PEST motif of *Xenopus* Ventx2 is a predicted target of MAPK ([Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}). Thus, we addressed whether MEK1 may participate in the control of Ventx2 stability. Western blot analysis of embryos injected with RNA encoding Myc-tagged Ventx2 confirmed the reported degradation after the onset of gastrulation ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). In contrast, in MEK1 morphants, Ventx2-Myc remained detectable up until mid-gastrula stage ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Next, we analyzed Ventx2-Myc distribution on sectioned blastula and gastrula embryos by immunofluorescence confocal microscopy. We found that MEK1 knockdown dramatically increased the number of Ventx2-Myc positive cells at both stages, when compared to control ([Figure 3A](#fig3){ref-type="fig"}). Careful inspection of blastula cells dividing along the animal-vegetal (apical-basal) axis of the tissue revealed that Ventx2-Myc was asymmetrically distributed in daughter cells in control but not in MEK1 morphant embryos ([Figure 3B and C](#fig3){ref-type="fig"}). In addition, a significant fraction of MEK1-depleted cells displayed Ventx2-Myc signal in the membrane cortex at both stages analyzed ([Figure 3A and B](#fig3){ref-type="fig"}). At blastula stage, Ventx2-Myc membrane association was polarized with respect to the plane of the tissue, with a clear basal enrichment ([Figure 3A and B](#fig3){ref-type="fig"}). No attempt was made at characterizing further the cortical localization of Ventx2. Altogether, our data reveal that MEK1 is required for Ventx2 asymmetric distribution during blastula cell division, and participates in developmentally regulated clearance of this protein in pluripotent embryonic cells.10.7554/eLife.21526.009Figure 3.MEK1 is required for Ventx2 clearance and asymmetric distribution during cell division.(**A,B**) Four-cell embryos were injected in each cell with 50 pg GFP-CAAX, 50 pg Ventx2-Myc, 50 pg 2SAVentx2-Myc RNAs, and 25 ng Mk-MO, as indicated. Embryos were fixed at blastula stage 9, or gastrula stage 11, cryosectioned and processed for anti-Myc (red), and anti-GFP (green) immunostaining, and DNA was stained with DAPI (blue). Graphs show the percentage of Myc positive nuclei (DAPI positive) over the total number of injected cells (GFP positive) from four independent experiments. (**B**) 3D reconstruction of confocal slices of mitotic Myc positive nuclei labeled by DAPI from stage nine sectioned embryos. Sister mitotic chromosomes are referred to as α (more intense Myc staining), and β (less intense Myc staining). The A-V arrows indicate the animal-vegetal axis. Note the asymmetric cortical Ventx2-Myc signal in the MEK1 morphant cell. (**C**). The graph shows the ratios of Myc signal intensity betweenα and β sister nuclei.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.009](10.7554/eLife.21526.009)10.7554/eLife.21526.010Figure 3---source data 1.Myc signal intensity ratios between daughter nuclei.Each value corresponds to the ratio calculated from one individual confocal slice between α and β daughter nuclei (see legend to [Figure 3](#fig3){ref-type="fig"} and Materials and methods for further details).**DOI:** [http://dx.doi.org/10.7554/eLife.21526.010](10.7554/eLife.21526.010)10.7554/eLife.21526.011Figure 3---figure supplement 1.Ventx2 degradation and asymmetric distribution require MEK1 activity.(**A**) In silico analysis of phosphorylation sites in the Ventx2 protein and prediction of kinases involved, with Kinasephos2 software. (**B**) Schematic representation of the Ventx2 protein. HD indicates the homeodomain (blue box), and the PEST destruction motif is highlighted in red. Note that Serine 140, which is required for Ventx2 degradation, is a predicted target of MAPK. (**C**) 50 pg Ventx2-Myc RNA was injected into both blastomeres at the two-cell stage. 50 pg GFP-Myc-RNA was co-injected as an internal loading control. Embryos were allowed to develop until the indicated stages, and exogenous Ventx2 was detected by anti-Myc immunostaining on Western blot. The graph shows the ratios of Ventx2-Myc over a-tub signals measured from the Western blot. (**D**) Four-cell embryos were injected in each cell with 50 pg GFP-CAAX, 50 pg Ventx2-Myc, 50 pg 2SAVentx2-Myc RNAs and with 25 ng Mk-MO as indicated. Embryos were fixed at blastula stage 9, cryosectioned and processed for anti-Myc (red), anti-GFP (green) and anti-g-tubulin (centrosomes, white) immunostaining, and DNA was stained with DAPI (blue). Panels represent compiled confocal slices to visualize entire mitotic nuclei.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.011](10.7554/eLife.21526.011)

The PEST destruction motif is required for destabilization and asymmetric distribution of Ventx2 {#s2-3}
------------------------------------------------------------------------------------------------

The above results raised the possibility that destabilization of Ventx2 in response to MEK1 is a key step for the transition between pluripotent and committed states of embryonic cells. To further evaluate this possibility, we injected a mutant form of Ventx2 lacking the functional PEST destruction motif. This stable form of Ventx2 was obtained through the substitution of two key serine residues (140 and 144) with alanine (2SAVentx2-Myc) and was demonstrated to be more efficient than the native form of Ventx2 in counteracting mesendoderm induction ([@bib41]). As predicted, 2SAVentx2-Myc was detectable in the nuclei of control cells, similar to Ventx2-Myc in MEK1 morphant cells ([Figure 3A](#fig3){ref-type="fig"}). Moreover, no marked asymmetric distribution of 2SAVentx2-Myc in daughter nuclei of dividing blastula cells was observed, suggesting that phosphorylation of the PEST motif is necessary to control Ventx2 asymmetric distribution ([Figure 3B and C](#fig3){ref-type="fig"}). Similarly to Ventx2-Myc in MEK-1 deficient cells, 2SAVentx2-Myc was detectable in the cortex of injected cells, particularly at gastrula stage ([Figure 3A](#fig3){ref-type="fig"}). Next, we combined anti-Myc and γ-tubulin staining to mark the centrosomes, so as to be able to distinguish mitotic phases ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Ventx2-Myc localized into the nuclei of blastula cells in prophase and MEK1 depletion did not affect this localization. Similarly, 2SAVentx2-Myc co-localized with chromosomes during prophase. Ventx2 is a phosphomitotic protein ([@bib36]), and it has been proposed that phosphorylation is required for disengagement of transcription factors from chromosomes in metaphase ([@bib36]). Accordingly, Ventx2-Myc was no longer associated with metaphasic chromosomes but rather with mitotic spindles. Interestingly, this change in distribution of Ventx2-Myc was independent from MEK1 activity or from the PEST destruction motif. Upon engagement into cytokinesis, the asymmetry of Ventx2-Myc in daughter nuclei became apparent. Quantification of signals intensity revealed that in control condition, one daughter nucleus contained on average 6.454 fold more Ventx2-Myc than the other daughter nucleus (s.e.m. ±0.5479), whereas this difference was significantly dampened in MEK1-deficient cells (mean ratios = 1.092; s.e.m. ±0.0447) and in 2SAVentx2-Myc injected cells (mean ratios = 1.910; s.e.m. ±0.1319)([Figure 3C](#fig3){ref-type="fig"}). Thus, the stabilization of exogenous Ventx2 through either MEK1 depletion or PEST motif mutation led to its symmetric distribution upon cell division.

Ventx2 inhibition by MEK1 is required for embryonic cell commitment {#s2-4}
-------------------------------------------------------------------

Our data indicate that Ventx2 expression, distribution and stability depend on MEK1 activity in vivo, raising the possibility of a causal relationship between the refractory behaviour of MEK1-depleted cells to differentiation and the activity of Ventx2. Consistent with this idea, 2SAVentx2-Myc, but not native Ventx2-Myc, caused a markedly high and ectopic expression of *pou5f3.*2 in late gastrula embryos, which was visible up until tailbud stage ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Furthermore, we found that 2SAVentx2-Myc but not Ventx2-Myc could counteract the conversion of ectoderm to mesoderm in response to a constitutively active form of MEK1 ([Figure 4B](#fig4){ref-type="fig"}). This result suggests that 2SAVentx2-Myc has become resistant to degradation induced by MEK1 and can efficiently maintain pluripotency and antagonize commitment in the presence of active MEK1. To test the functional importance of the antagonism between MEK1 and Ventx2 in the transition from pluripotent to committed states, we combined Mk-MO with Ventx2 MO ([@bib31]). RT-qPCR and in situ hybridization analyses revealed that Ventx2 MO injection caused the down-regulation of *ventx1* and *ventx3* expression, suggesting that a large part of Ventx activity is missing in such embryos ([Figure 4---figure supplement 1B and C](#fig4s1){ref-type="fig"}). As predicted, MEK1-Ventx2 double morphant cells regained the competence to respond to exogenous inducers and thus to express epidermal, neural, mesodermal and endodermal markers in response to BMP4, NOGGIN, low and high doses of NODAL, respectively ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, the expression of the lineage-restricted markers *foxd5*, *gsc*, *t/bra*, and *xk81a1* was rescued in MEK1-Ventx2 double morphant embryos ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Conversely, the sustained expression of *pou5f3.2* caused by MEK1 depletion was counteracted by concomitant Ventx2 knockdown ([Figure 4D](#fig4){ref-type="fig"}). Finally, morphogenesis and axis formation was also partially restored in MEK1-Ventx2 double morphant embryos ([Figure 4E](#fig4){ref-type="fig"}). Altogether, these data indicate that MEK1 and Ventx2 functionally interact during the transition of pluripotent cells from refractory to responsive states.10.7554/eLife.21526.012Figure 4.Ventx2 knockdown rescues the competence of MEK1-deficient cells to differentiate.(**A**) 4 cell embryos were injected in each cell with 50 pg Ventx2-Myc or 50 pg 2SAVentx2-Myc RNAs, and processed for WISH analysis at late gastrula stage 13 with *pou5f3.2* probe. Stabilized 2SAVentx2 maintains ectopic *pou5f3.2* expression. Top row dorsal view, bottom row lateral view. (**B**) Embryos injected as in (**A**), with or without 500 pg CA-Mk RNA per blastomere, were processed for WISH analysis at early gastrula stage 10.5 with *t/bra* probe. The number of embryos with ectopic *t/bra* expression is indicated in each condition. Stabilized 2SAVentx2 counteracts CA-Mk activity. Top row animal view, bottom row lateral view. (**C**) Sixteen-cell embryos were injected in one animal blastomere with 50 pg GFP-CAAX RNA, 25 ng Mk-MO and 7.5 ng Vx2-MO, as indicated. Next, these embryos were injected at blastula stage 8.5 with recombinant BMP4 (2 ng for *xk81a1* induction, animal view), NODAL (5 ng for *t/bra* induction, lateral view; 50 ng for *mixer* (endoderm) induction, animal view), or NOGGIN (36 ng for *sox2* induction, animal view) proteins into the blastocoel, collected at early gastrula stage 10.5, and processed for WISH. Mk-MO injected domains are indicated by white arrows. (**D**) Four-cell embryos were injected in each blastomere with 25 ng Mk-MO alone or with 7.5 ng Vx2-MO, collected at late gastrula stage 13 and processed for WISH with *pou5f3.2* probe. (**E**) Embryos injected as in (**D**) were collected at tailbud stage 25, processed for WISH with *sox2* probe, and scored. Ventx2 knockdown partially restores development of MEK1-deficient embryos. MEK1/Ventx2 double knockdown rescue assays were repeated five times. In A and C, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.012](10.7554/eLife.21526.012)10.7554/eLife.21526.013Figure 4---figure supplement 1.Ventx2 knockdown restores germ-layer formation in MEK1-deficient embryos.(**A**) Four-cell embryos were injected with 50 pg 2SAVentx2-Myc RNA per cell, fixed at tailbud stage 25 and processed for WISH with *pou5f3.2* probe. (**B**) Four-cell embryos were injected with 30 ng Ventx2-MO (Vx2-MO) per blastomere, collected at stage 10.5 and processed for RT-qPCR. (**C**) Embryos injected as in B were processed for WISH analysis at early gastrula stage 10.5 with *ventx1* and *gsc* probes (vegetal view). (**D**). Four-cell embryos were injected with 25 ng Mk-MO, with or without 7.5 ng Vx2-MO, in each blastomere, collected at gastrula stage 10.5, and processed for WISH with indicated probes. Note that embryos stained for *xk81a1* (epidermis) were injected in one ventral animal blastomere at 16 cell stage and collected at late gastrula stage 13. Embryos stained for *gsc* were hemisectioned prior to staining to improve probe penetration. In A and D, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated. For the RT-qPCR graph, error bars represent s.e.m. values of three independent experiments with two technical duplicates. For statistical analysis, samples from injected embryos were compared with samples from uninjected control embryos by Unpaired Student's t-test. \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.21526.013](10.7554/eLife.21526.013)

Discussion {#s3}
==========

The findings presented here reveal a mechanism for the control of embryonic cell competence to differentiate, which is linked to the spatio-temporal stability of pluripotency factors in vivo. Specifically, MEK1 activity counteracts Ventx2 activity, both at transcriptional and post-translational levels, which ensures the transition from refractory to responsive states of embryonic cells. In pluripotent blastula cells, MEK1 is necessary for asymmetric distribution of Ventx2 during cell division, generating Ventx2 positive and negative daughter nuclei. By promoting early heterogeneous distribution together with developmentally regulated nuclear clearance of Ventx2, we propose that MEK1 is a fundamental cue for pluripotency state extinction in vivo. To our knowledge, this is the first reported regulatory mechanism that correlates the asymmetric distribution and stability of a transcription factor with cell pluripotency in vertebrate embryos. Although we used exogenous Ventx2 tagged proteins to reveal this mechanism, the rescue of cell differentiation in double MEK1/Ventx2 morphants suggests that endogenous Ventx2 is under the same control. Our data are consistent with a recent finding, whereby the Wnt/β-catenin pathway orients asymmetric cell division of mESCs and generates unequal distribution of pluripotency factors, which impacts on cell potency in vitro ([@bib16]).

How does MEK1 regulate Ventx2 asymmetry and stability in *Xenopus* embryonic cells? Ventx2 phosphorylation in the PEST motif was shown to be required for ubiquitination and degradation ([@bib41]). Thus, our observation that mutation of the Ventx2 PEST motif prevents unequal distribution in daughter nuclei suggests that the asymmetric distribution of Ventx2 during mitosis and proteasome activity may be related. In the simplest scenario, MEK1 may act directly or through MAPK to phosphorylate the Ventx2 PEST motif and promote Ventx2 proteolysis. Supporting this hypothesis, the MAPK ERK1 is a known regulator of pluripotency factor stability in vitro ([@bib34]; [@bib18]), and MAPK is predicted to phosphorylate one of the key serine residues in the Ventx2 PEST domain. We note, however, that MEK1 depletion caused stronger responses than 2SAVentx2 injection, suggesting that MEK1 regulates pluripotency through additional residues in Ventx2 and/or through additional effectors. Interestingly, the BMP signal mediator Smad1 was also found to be asymmetrically distributed during somatic cell division, when marked for degradation by MAPK ([@bib15]). There, phosphorylation by MAPK triggers a subsequent phosphorylation event by GSK3, followed by polyubiquitinylation and proteosomal degradation of activated Smad1, leading to BMP signal termination. In contrast, we did not find evidence of GSK3 involvement in the repression of pluripotency genes and in Ventx2 degradation ([Supplementary file 1](#SD3-data){ref-type="supplementary-material"}), consistent with previous data ([@bib41]). Thus, MEK1 may trigger important proteolytic events in early embryos, independently of GSK3. Although it is tempting to think that MEK1 activity itself may be polarized during division of pluripotent embryonic cells, evidence for such mechanism is lacking in the literature. Alternatively, it is possible that MEK1 controls downstream regulators endowed with asymmetric distribution or activity. For instance, ERK1 was shown to antagonize the polarized PAR-1 kinase during asymmetric cell divisions of the early *C. elegans* embryo ([@bib35]). Also related to this idea, asymmetric proteasome segregation was shown to control polarized degradation of the phosphorylated transcription factor T-bet during T lymphocyte division ([@bib8]). Finally, it remains possible that MEK1 activity would be antagonized by one or several phosphatases that would protect Ventx2 from degradation, and would somehow contribute to its unequal inheritance in daughter nuclei. Such a balance between the PAR-1 kinase and PP2A phosphatase was shown to control the state of PAR-3 phosphorylation and thus the polarity of dividing embryonic neuroblasts in *Drosophila* ([@bib19]). Future work should address the precise mechanism of action of MEK1 upon Ventx2 during division of *Xenopus* pluripotent cells, a question of high relevance to stem cell biology.

Unexpectedly, we observed that MEK1 depletion caused Ventx2 asymmetric localization in the basal membrane cortex of blastula cells. This localization was not apparent in control cells, suggesting that it does not simply reflect the over-abundance of Ventx2 protein due to synthetic RNA injection. Rather, this suggests that MEK1 actively prevents membrane association of Ventx2. As stabilized 2SAVentx2 also localized at membranes, this territory may represent a storage compartment for Ventx2 protein. Thus, it will be important to evaluate whether the endogenous Ventx2 protein also displays this unexpected localization in normal or MEK1 morphant embryos. The asymmetric localization of Ventx2 at the basal membrane cortex of MEK1 depleted cells suggests possible links between MEK1 and polarity effectors such as PAR-1 and aPKC ([@bib26]; [@bib7]). In relevance to our observations, it was reported that Pou5f1 and Pou5f3 proteins localize at the cell membrane both in mESCs and in *Xenopus* animal pole cells, where they form a complex with E-cadherin and β-catenin ([@bib21]; [@bib14]). Since Ventx2 can physically interact with Pou5f3 proteins ([@bib5]), we speculate that MEK1 may be required to destabilize the interaction between Ventx2 and Pou5f3, not only in the nucleus but also at the membrane, further enhancing the competence of embryonic cells to exit pluripotency.

Ventx2 is a *bona fide* marker of pluripotency during *Xenopus* embryogenesis ([@bib31]; [@bib3]), and the above data indicate that its activity must be inhibited for cells to engage into differentiation pathways. However, the link between *Ventx* genes and pluripotency in other vertebrates, particularly in mammals, has not been actively studied. This may reflect the absence of Ventx orthologs in the rodent genus, although a unique *VENTX* gene is present in human ([Supplementary file 3](#SD5-data){ref-type="supplementary-material"}). Phylogenetic and synteny analyses suggest that a *Ventx* gene appeared at the base of gnathostome evolution, and its prototypical genomic locus has not changed for 450 My ([Supplementary files 2](#SD4-data){ref-type="supplementary-material"} and [3](#SD5-data){ref-type="supplementary-material"}). Human *VENTX* is the ortholog of *Xenopus*, birds, sauropside and coelacanth *Ventx2* ([Supplementary files 2](#SD4-data){ref-type="supplementary-material"} and [4](#SD6-data){ref-type="supplementary-material"}). Interestingly, a recent study reported a 6-fold up-regulation of *VENTX* (higher than *NANOG*, *PRDM14*, *POU5F1* and *SOX2*) in naive hESCs compared to conventional hESCs ([@bib39]). In this study, naive hESCs were obtained in the presence of inhibitors of five kinases, including MEK1, suggesting that repression of VENTX by MEK1 may be conserved in human pluripotent cells. Beyond such circumstantial evidence, the next question is whether VENTX is an important regulator of pluripotency in human, as it is in *Xenopus*. Initial support for this idea comes from the identification of VENTX in an unbiased functional screen as a positive regulator of *Pou5f1* expression in hESCs ([@bib9]). Together with the results reported here and elsewhere ([@bib31]; [@bib3]), such evidence certainly grants more detailed analysis regarding the role of VENTX in the human pluripotency network. As VENTX is absent in rodents, we propose that *Xenopus* represents an appropriate and powerful model to undertake comparative approaches with human and shed light on the control mechanisms of pluripotency in vivo and at single cell level.

Materials and methods {#s4}
=====================

*Xenopus* general procedures and micro-injections {#s4-1}
-------------------------------------------------

*Xenopus laevis* embryos were obtained from lab-bred adults (Nasco) by in vitro fertilization, de-jellied, injected and cultured in modified Barth's solution (MBS) as previously described ([@bib23]). Capped mRNAs for injection were synthesized with mMessage mMachine kits (Ambion, Austin, Texas). When necessary, lineage tracing was achieved through co-injection of Fluorescent Lysine DeXtran (FLDX) or membrane bound GFP-CAAX revealed by anti-FLDX or anti-GFP immune staining. The pCS2-Ventx2-Myc and pCS2-2SAVentx2-Myc (previously reported as *Xom* but now referred as *ventx2.2,* Xenbase-*Xenopus* Genome Initiative) plasmids were used as described ([@bib41]). The rabbit pCS2-CA-MEK1 plasmid was linearized with NcoI and mRNA synthesized with SP6 polymerase. To rescue Mk morphant embryos, the hamster pECE-MEK1 plasmid ([@bib27]) was digested with XbaI and HindIII to isolate MEK1 ORF, which was subsequently cloned into the pSP64T vector. This new construct was linearized with BamHI and mRNA synthesized with SP6 polymerase. The dominant-negative GSK3 (dnGSK3) expression construct was used as previously described ([@bib28]). Mk-MO ATG (5'-TGGGCGTAGGCTTCTTTTTAGGCAT--3') and Mk-MO (5'-TGAGTGGAGAGCAGAGCGAGTGCCC--3') were purchased from GeneTools, LLC. The Vx2-MO was described in ([@bib30]). BMP4 (R&D System; 314 BP), NODAL (R&D System; 1315-ND) and NOGGIN (R&D System; 334 NG) proteins were resuspended as recommended by manufacturers, and injected through the animal pole into the blastocoelic cavity of blastula stage embryos, or added in 1xMBS to culture animal cap explants. Throughout the study, each injection experiment was performed three or more times on different batches of embryos. Rescue experiments using Mk-MO and wild-type MEK1 were repeated five times, and blastopore closure quantification was performed on three independent experiments as previously described ([@bib24]). The number of embryos analyzed by condition ranged between 20 and 100. In total, over 700 MEK1 morphant embryos were analyzed with various methods and markers, with a very high penetrance of the reported phenotypes.

Stainings {#s4-2}
---------

Whole-mount chromogenic in situ hybridization (WISH) was performed as previously described ([@bib23]), and photographs were taken on a Zeiss stereomicroscope equipped with a DS-L2 Nikon camera. Plasmids used to make antisense riboprobes are described in [Supplementary file 5](#SD7-data){ref-type="supplementary-material"}. FLDX was detected by incubation with alkaline phosphatase conjugated anti-fluorescein antibody (dilution 1/10,000; Roche). Sections were prepared and immune staining was performed as previously described ([@bib10]; [@bib6]). Primary antibodies were as follows: anti-Myc (9E10; Santa Cruz Biotech, dilution 1/300 RRID:[AB_627268](https://scicrunch.org/resolver/AB_627268)), anti-GFP (GFP-1020; 2BScientific; dilution 1/1000 RRID:[AB_10000240](https://scicrunch.org/resolver/AB_10000240)), anti-γ-Tubulin (ab16504; Abcam; dilution 1/1000 RRID:[AB_443396](https://scicrunch.org/resolver/AB_443396)), anti-phospho-MEK1 (9121; Cell Signaling Technology; dilution 1/400 RRID:[AB_331648](https://scicrunch.org/resolver/AB_331648)). Alexa Fluor secondary antibodies (Molecular Probes) were used at a dilution of 1:500. To stain DNA, DAPI (Invitrogen), at a final concentration of 10 μg/ml, was added to one of the final MABX washes and incubated for 3 min at room temperature. Stained sections were mounted with Fluoromount G (Fluoprobes) and allowed to dry before imaging on a Zeiss LSM780 confocal microscope. Images were acquired as eight bit/channel and with 1024 × 1024 pixel resolution, and processed with ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)) for maximum intensity *z*-projection and/or merge of channels. *Z*-projections of green channel images were used to count GFP-positive injected cells. The percentage of Ventx2 positive nuclei was determined using a merge of Myc and GFP channels in order to consider only co-injected cells. For blastula stage 9 quantification of the percentage of Myc positive nuclei, a total of 251, 244 and 238 GFP-positive cells from Ventx2-Myc, Mk-MO+Ventx2-Myc, 2SAVentx2-Myc injected embryos was analyzed. For gastrula stage 11 quantification of the percentage of Myc positive nuclei, a total of 213, 238 and 207 GFP-positive cells from Ventx2-Myc, Mk-MO+Ventx2-Myc, 2SAVentx2-Myc injected embryos was analyzed. For statistical analyses, samples from Mk-MO+Ventx2-Myc and 2SAVentx2-Myc injected embryos were compared with samples from Ventx2-Myc injected embryos (as control) by Unpaired Student's t-test with Welch's correction (95% of confidence interval), and error bars represent s.e.m. values. To analyze dividing cells, fluorescence intensity levels of Myc-tagged Ventx2 proteins were measured using ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)), from stacks of confocal images from 5 to 10 sections per independent experiment (at least four for each stage analyzed). For quantification of Myc-intensity ratios between α and β daughter nuclei, stack-by-stack calculation of the ratios of fluorescence intensity of Ventx2-Myc (n = 42 stacks) alone or with Mk-MO (n = 51 stacks), or of 2SAVentx2-Myc (n = 56 stacks) from four dividing cells per case was performed. Non-parametric Mann-Whitney *U* test (95% confidence interval) was used to assess statistical differences among samples and error bars represent s.e.m. values. Statistical analysis was made using GraphPad Prism 6 (RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)). For western blotting, embryos were snap-frozen and processed as described ([@bib22]). Proteins were transferred to PVDF membranes (Bio-Rad) and analyzed by immunoblotting with appropriate primary antibodies: anti-Myc (9E10; Santa Cruz Biotech, dilution 1/100 RRID:[AB_627268](https://scicrunch.org/resolver/AB_627268)), anti-GFP (GFP-1020; 2BScientific; dilution 1/200 RRID:[AB_10000240](https://scicrunch.org/resolver/AB_10000240)); anti-MEK1 (4A5; Cliniscience; dilution 1/1000 RRID:[AB_2042302](https://scicrunch.org/resolver/AB_2042302)), anti-α-tubulin (DM1A; AbCam; dilution 1/1000 RRID:[AB_2241126](https://scicrunch.org/resolver/AB_2241126)). HRP-conjugated were used as secondary antibodies (1/5000, Dako). Immunoreactive bands were detected using the Immobilon ECL Kit (Merck Millipore) on a LAS-3000 imager (Fujifilm).

Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) {#s4-3}
----------------------------------------------------------------------

Mk-MO injected and uninjected (controls) embryos were grown until gastrula stage 10.5, and then processed for RT-qPCR, as previously described ([@bib31]; [@bib6]). Ten embryos per biological replicate were used. Animal pole explants from injected and uninjected embryos were taken at blastula stage 9, grown in 1X MBS until late gastrula stage 13, and processed for RT-qPCR. 15 animal pole explants per biological replicate were used. RT-qPCR Primers are listed in [Supplementary file 6](#SD8-data){ref-type="supplementary-material"}. Statistical analyses were done using GraphPad Prism 6 (RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798))
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###### GSK3 is not a negative regulator of the pluripotency gene network and is not required for MEK1-dependent Ventx2 clearance in vivo.

\(A\) Four-cell embryos were injected with 300 pg DN-GSK3 RNA per blastomere. Embryos were collected at stage 25 and processed for WISH analysis with *sox2* probe. DN-GSK3 efficiently induced secondary body axes, indicating that the dose used was functional. (B) Embryos injected as in (A), were collected at stage 10.5 and processed for RT-qPCR. (C-D) Embryos injected as in (A) were processed for WISH analysis at early gastrula stage 10.5 with *gsc* (C, vegetal view) and *ventx2* (D, top: vegetal view, bottom: animal view) probes. (E) Embryos injected at the 8 cell stage with 300 pg DN-GSK3 RNA in one dorsal animal blastomere were processed for WISH analysis at late gastrula stage 13 with *pou5f3.2* and *ventx2* probes (anterior view). (F-G) Four-cell embryos were injected in each cell with 50 pg GFP-CAAX, 50 pg Ventx2-Myc, and 25 ng Mk-MO (F), or 50 pg GFP-CAAX, 50 pg Ventx2-Myc and 300 pg of DN-GSK3 (G) Animal caps were explanted at blastula stage nine and cultured until gastrula stage 11, fixed and processed for anti-Myc (red), and anti-GFP (green) immunostaining, and DNA was stained with DAPI (blue). Note that Ventx2-Myc is detectable only in MEK1 depleted caps. For the qPCR graph, error bars represent s.e.m. values of three independent experiments with two technical duplicates. For statistical analyses, samples were compared with the respective control by Unpaired Student's t-test. \*p\<0.05, \*\*p\<0.005. In C, D and E, the number of embryos exemplified by the photograph over the total number of embryos analyzed is indicated. In F and G scale bar is 20 μm.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.014](10.7554/eLife.21526.014)

10.7554/eLife.21526.015

###### Phylogenetic tree of *Ventx* deuterostome genes.

Boxes indicate members with orthology relationship, like coelacanth *Ventx*, *Xenopus Ventx2* and human *VENTX* (blue arrows). Sequences were collected from ENSEMBL, JGI, A-STAR and NCBI public databases (see [Supplementary file 4](#SD6-data){ref-type="supplementary-material"}). Ventx homeodomain sequences were aligned using Jalview software (RRID:[SCR_006459](https://scicrunch.org/resolver/SCR_006459)) and the phylogenetic tree was obtained by Neighbor Joining analysis of percentage identity.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.015](10.7554/eLife.21526.015)

10.7554/eLife.21526.016

###### The Evolutionary history of Ventx family genes.

\(A\) Synteny of the *Ventx* genomic region in gnathostomes. Blue dotted boxes indicate species-specific gene duplication events. Note that a triplication event, giving rise to *Ventx1*, *Ventx2* and *Ventx3*, occurred in the last common ancestor of tetrapods. One or more *Ventx* paralogs was subsequently lost during squamata, archosaura and testudina evolution. Mammals lost both *Ventx1* and *Ventx3* paralogs and exclusively kept *Ventx2*. Mouse represents an extreme case with a total loss of *Ventx* genes. (B) Simplified tree of vertebrates, which displays typical situations regarding the number of *Ventx* genes in main evolutionary branches.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.016](10.7554/eLife.21526.016)
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###### EMBOSS prediction of PEST destruction motifs in Ventx orthologs.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.017](10.7554/eLife.21526.017)

10.7554/eLife.21526.018

###### Probes used for WISH.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.018](10.7554/eLife.21526.018)

10.7554/eLife.21526.019

###### Primers used for RT-QPCR.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.019](10.7554/eLife.21526.019)

10.7554/eLife.21526.020

###### Related to [Supplementary file 2](#SD4-data){ref-type="supplementary-material"}.

VENTX homeodomain sequences.

**DOI:** [http://dx.doi.org/10.7554/eLife.21526.020](10.7554/eLife.21526.020)
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\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Lineage commitment of embryonic cells involves MEK1-dependent clearance of pluripotency regulator Ventx2\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Although we agree that your work is of potential interest, further experimentation is necessary to convince them of the validity of your conclusions. Among other studies, you would need to use animal caps instead of whole embryos, carry out a more comprehensive analysis to definitely rule out roles for other signaling pathways, perform other types of confirmatory experiments that don\'t rely on the use of morpholinos and address the problem of maternally-contributed MEK1 as a confounding variable.

Reviewer \#1:

This manuscript uses the intact *Xenopus laevis* embryo as a model system to elucidate the molecular mechanisms involved in the regulation of pluripotency, focussing on MEK1 (*map2k1*) regulation of Ventx2.2 (encoded by one of a cluster of six related Ventx genes in *X. laevis*). Ventx proteins, absent in the mouse but present in human, appear to be functionally analogous to the transcription factor *Nanog* (absent in *X. laevis*).

The authors demonstrate that MEK1 activity acts to modulate exogenous (and presumably endogenous) Ventx2.2 protein stability; in response to morpholino-mediated down-regulation of MEK1, Ventx2.2 levels increase, the post-mitotic asymmetry in nuclear (exogenous) Ventx2.2 protein disappears, and cellular differentiation is suppressed. The cell differentiation phenotype is rescued in MEK1 morphant embryos by the co-injection of a translation-blocking anti-Ventx2 morpholino.

Experimental design question: While the authors recognize that *Xenopus* ectodermal explants (animal caps) are effectively pluripotent they have chosen to carry out their studies in whole embryos, which are subject to the complexities of inductive interactions and morphogenetic processes.

Perhaps they could explain their decision, and comment on whether they have examined differentiation in the simpler animal cap system.

Reviewer \#2:

This work explores the role of MEK and the transcription factor Ventx2 (similar to mammalian *Nanog*) in regulating the transition from pluripotency to lineage commitment in *Xenopus*. The authors show that MEK knockdown results in a failure of mesoderm and ectoderm development, based on marker gene analysis. The authors further provide evidence that MEK acts by negatively regulating the mRNA levels and protein stability of Ventx2. They report that Ventx2 protein localizes to centrosomes during mitosis and is asymmetrically distribute to one daughter cell. They conclude that in order for embryonic cells to transition from pluripotency to lineage specification, MEK down regulates Ventx2, which would otherwise maintain the pluripotent state much like *Nanog* does in mammals.

The data supporting the conclusion that MEK is required for lineage specification in part through Ventx2 phosphorylation and degradation is strong, but not entirely novel (see below). The main weakness is with the conclusion that MEK inhibition and Ventx2 maintain pluripotency in *Xenopus*, which is not very well supported. Although previous reports suggest that Ventx2 might promote pluripotency, this data is not very robust and is built largely on the fact that Ventx2 can repress differentiation based on a limited marker analysis. Many studies over the past 20 years have shown that MEK and Ventx are involved in mesoderm and neuro-ectoderm development (e.g. PMIDs: 7789277, 7541116, 17525737). In the case of MEK this was attributed to the inducing role of FGF, which has not been ruled out here. Given these previous studies the authors need more rigorous, genome wide analysis, showing that what they are observing is not just the known role of MEK and Ventx in specific lineages. A good test of their hypothesis would be to deplete MEK from animal caps and/or embryos and look at ability of BMP, Activin or Wnt to induce any lineages (including endoderm) by RNA-seq or microarray. Then use a more comprehensive markers analysis (in situ or RT-PCR of a broader panel) to test whether combined MEK and Ventx2 depletion restored all the lineages. Without a genome wide analysis, or some functional assay, showing that the cells cannot differentiate into any lineages it is impossible to conclude that the pluripotency to commitment transition is really involved.

In addition it has already been shown that Ventx2 degradation is promoted GSK3 phosphorylation (PMID:12408807). Since GSK3 has a preference for residues that are primed by MAPK phosphorylation the observation that MEK is required for Ventx2 phosphorylation and degradation is not surprising. In fact the authors should check whether the MEK regulated activity they observe is GSK3-dependent. It is known that Smad1 is phosphorylated by MEK and GSK3, and recruited to the centrosome where it is asymmetrically localized and degraded (PMID:18045539), similar to what is observed here.

Given the known role of MEK (and GSK-3) as well as *Nanog* in mammalian pluripotency, the model that the authors propose is very attractive. If they could provide more rigorous data to support their claim then this would be an important advance.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Lineage commitment of embryonic cells involves MEK1-dependent clearance of pluripotency regulator Ventx2\" for further consideration at *eLife*. Your revised article has been evaluated by Marianne Bronner (Senior Editor), a Reviewing Editor, and one reviewer.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below. I would like to stress that *eLife* does not normally allow for multiple rounds of review so it is essential that you complete these relatively minor but important revisions or the paper will not be considered further. However, we will understand if you would prefer to withdraw the paper in the event you are not prepared to perform this essential additional work.

1\) RNA encoding the wild type form of MEK1 rescues the MEK1 morpholino phenotype. Seems like a straightforward and necessary experiment that would justify generating the construct.

2\) Since it could be done with simple qRT-PCR, it seems important to know whether the Ventx2 morpholino influences the expression of any of the other Ventx genes?

3\) Rather than argue the point, the authors should repeat the study on GSK3-MEK interaction as previously suggested (\"In fact the authors should check whether the MEK regulated activity they observe is GSK3-dependent.\"), as it would both solidify previous conclusions and help define the mechanism reported here.

4\) As previously suggested, please test the hypothesis by depleting MEK from animal caps and/or embryos and look at ability of BMP, Activin or Wnt to induce any lineages), would address my concerns about whole embryos versus animal caps. In this case, qRT-PCR of a few diagnostic markers (rather than RNA SEQ or microarray analyses) should be sufficient.

10.7554/eLife.21526.022

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Although we agree that your work is of potential interest, further experimentation is necessary to convince them of the validity of your conclusions. Among other studies, you would need to use animal caps instead of whole embryos, carry out a more comprehensive analysis to definitely rule out roles for other signaling pathways, perform other types of confirmatory experiments that don\'t rely on the use of morpholinos and address the problem of maternally-contributed MEK1 as a confounding variable.

Reviewer \#1:

This manuscript uses the intact Xenopus laevis embryo as a model system to elucidate the molecular mechanisms involved in the regulation of pluripotency, focussing on MEK1 (map2k1) regulation of Ventx2.2 (encoded by one of a cluster of six related Ventx genes in X. laevis). Ventx proteins, absent in the mouse but present in human, appear to be functionally analogous to the transcription factor Nanog (absent in X. laevis).

The authors demonstrate that MEK1 activity acts to modulate exogenous (and presumably endogenous) Ventx2.2 protein stability; in response to morpholino-mediated down-regulation of MEK1, Ventx2.2 levels increase, the post-mitotic asymmetry in nuclear (exogenous) Ventx2.2 protein disappears, and cellular differentiation is suppressed. The cell differentiation phenotype is rescued in MEK1 morphant embryos by the co-injection of a translation-blocking anti-Ventx2 morpholino.

Experimental design question: While the authors recognize that Xenopus ectodermal explants (animal caps) are effectively pluripotent they have chosen to carry out their studies in whole embryos, which are subject to the complexities of inductive interactions and morphogenetic processes.

Perhaps they could explain their decision, and comment on whether they have examined differentiation in the simpler animal cap system.

Cells of the animal hemisphere of the *Xenopus* blastula embryo are indeed pluripotent, and keep this property when explanted. However, while animal caps have allowed to reveal the inductive capacities of many signalling pathways and transcription factors, they do not accurately reflect in vivo developmental potential (e.g. PMID: 15590738). In particular, injury due to dissection is known to cause ERK phosphorylation, which could complicate our interpretations. Inconsistencies have also been reported in multiple occasions when comparing mouse ES cells to mouse pre-implantation embryos. Thus, we designed our assays to study fate commitment of pluripotent cells in vivo, which allowed us to draw clear conclusions. 1) MEK1 knockdown prevents natural embryonic inductions, and causes the maintenance of high levels of pluripotency genes Ventx2 and Pou5f3.2. The comparison of small Mk-MO injected clones to wild-type surrounding cells in embryos that underwent normal morphogenesis addresses one of the concerns of our reviewer (see [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). We also would like to stress that pluripotency gene up-regulation upon MEK1 knockdown in animal caps was reported by RT-qPCR ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}). 2) In intact embryos, MEK1-deficient animal cells do not respond to exogenous inducers ([Figure 2A](#fig2){ref-type="fig"}), but differentiation is restored when Ventx2 is concomitantly knocked down ([Figure 4C-E](#fig4){ref-type="fig"}). At best, we can anticipate the same information to be collected from in vitro animal cap assays. 3) Using intact embryos, we were able to analyse sub-cellular Ventx2 protein distribution in animal cells that maintained a natural tissue polarity, which is known to be lost in animal caps.

Reviewer \#2:

This work explores the role of MEK and the transcription factor Ventx2 (similar to mammalian Nanog) in regulating the transition from pluripotency to lineage commitment in Xenopus. The authors show that MEK knockdown results in a failure of mesoderm and ectoderm development, based on marker gene analysis. The authors further provide evidence that MEK acts by negatively regulating the mRNA levels and protein stability of Ventx2. They report that Ventx2 protein localizes to centrosomes during mitosis and is asymmetrically distribute to one daughter cell. They conclude that in order for embryonic cells to transition from pluripotency to lineage specification, MEK down regulates Ventx2, which would otherwise maintain the pluripotent state much like Nanog does in mammals.

We did not mention a centrosomal localization of Ventx2 protein during mitosis. We mentioned that: \"...Ventx2-Myc was no longer associated with metaphasic chromosomes but rather with mitotic spindles.\"

The data supporting the conclusion that MEK is required for lineage specification in part through Ventx2 phosphorylation and degradation is strong, but not entirely novel (see below). The main weakness is with the conclusion that MEK inhibition and Ventx2 maintain pluripotency in Xenopus, which is not very well supported. Although previous reports suggest that Ventx2 might promote pluripotency, this data is not very robust and is built largely on the fact that Ventx2 can repress differentiation based on a limited marker analysis.

Pluripotency regulators are indeed characterized by their capacity to refrain differentiation. Ventx2 matches this condition, based on several independent reports, and is used by *Xenopus* experts as a marker of the pluripotent cell state (e.g. PMID: 24210613; 25931449). An unbiased screen identified Ventx as a positive regulator of pluripotency in human ESCs (PMID: 20953172). In zebrafish, a Ventx ortholog known as Vox can reprogram embryonic endodermal cells to a pluripotent state (PMID: 23364327). Thus, the link between Ventx genes and pluripotency is based on robust data in multiple models. Likewise, MEK1 is a known inhibitor of pluripotency in ES cells and our data further support this idea. Finally, Oct4 genes are widely accepted as universal markers of pluripotency in vertebrates and we report here that *Xenopus* Pou5f3.2 (one of several Oct4 orthologs) is repressed by MEK1 through Ventx2.

Many studies over the past 20 years have shown that MEK and Ventx are involved in mesoderm and neuro-ectoderm development (e.g. PMIDs: 7789277, 7541116, 17525737). In the case of MEK this was attributed to the inducing role of FGF, which has not been ruled out here.

MEK1 is indeed required for inductions by FGF, and it is not our intention to rule out this function. What we instead suggest is that when a pluripotent cell is presented with FGF or other RTK ligands, it is able to exit pluripotency and commit to various lineages, depending on the cues it is exposed to. Thus, induction depends on pluripotency exit and these two features are difficult to uncouple. Our work represents a substantial progress in showing that MEK1 knockdown causes the maintenance of two core pluripotency regulators, Ventx2 and *Pou5f3.2*, one of which represents a functional block to differentiation.

Given these previous studies the authors need more rigorous, genome wide analysis, showing that what they are observing is not just the known role of MEK and Ventx in specific lineages. A good test of their hypothesis would be to deplete MEK from animal caps and/or embryos and look at ability of BMP, Activin or Wnt to induce any lineages (including endoderm) by RNA-seq or microarray. Then use a more comprehensive markers analysis (in situ or RT-PCR of a broader panel) to test whether combined MEK and Ventx2 depletion restored all the lineages. Without a genome wide analysis, or some functional assay, showing that the cells cannot differentiate into any lineages it is impossible to conclude that the pluripotency to commitment transition is really involved.

Our reviewer suggests to use genome-wide analysis to evaluate lineage induction in MEK1 and MEK1/Ventx2 morphant situations. We feel that this is overshooting. We used few but extremely well characterized early lineage markers to reveal that MEK1 morphant cells become incompetent to respond to inducers of epidermal, neural, mesodermal and endodermal lineages, and regain this capacity when Ventx2 is also inhibited. What matters here is the competence or incompetence of embryonic cells to respond to inducers. This conclusion will be unchanged if genome-wide analysis is applied. What may be revealed by genome-wide analysis is the identity of putative additional pluripotency regulators; however, this is beyond the scope of our study, which focuses on the specific relationship between MEK1 and Ventx2.

In addition it has already been shown that Ventx2 degradation is promoted GSK3 phosphorylation (PMID:12408807). Since GSK3 has a preference for residues that are primed by MAPK phosphorylation the observation that MEK is required for Ventx2 phosphorylation and degradation is not surprising. In fact the authors should check whether the MEK regulated activity they observe is GSK3-dependent. It is known that Smad1 is phosphorylated by MEK and GSK3, and recruited to the centrosome where it is asymmetrically localized and degraded (PMID:18045539), similar to what is observed here.

The study that reported Ventx2 (also called Xom) degradation in gastrula embryos actually indicated that GSK3 activity is *not* required for degradation (PMID: 12408807 p561). Thus, the degradation mechanism induced by ERK/GSK3 sequential phosphorylation does not apply to Ventx2.

Given the known role of MEK (and GSK-3) as well as Nanog in mammalian pluripotency, the model that the authors propose is very attractive. If they could provide more rigorous data to support their claim then this would be an important advance.

We thank our reviewer for his/her appreciation of our proposed model. We feel, however, that our data are rigorous, notwithstanding the lack of genome-wide analysis.

\[Editors' note: the author responses to the re-review follow.\]

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below. I would like to stress that eLife does not normally allow for multiple rounds of review so it is essential that you complete these relatively minor but important revisions or the paper will not be considered further. However, we will understand if you would prefer to withdraw the paper in the event you are not prepared to perform this essential additional work.

1\) RNA encoding the wild type form of MEK1 rescues the MEK1 morpholino phenotype. Seems like a straightforward and necessary experiment that would justify generating the construct.

To address this request, we injected synthetic mRNA encoding a wild-type version of hamster MEK1 ORF into Mk morphant embryos. There was no overlap between Mk-MO and hamster MEK1 mRNA. To further avoid in vitro non-specific interaction between these two molecules, they were injected separately. Wildtype MEK1 could largely restore gastrulation, as well as axial mesoderm and neurectoderm specification. These results now replace those initially obtained with a constitutively active version of MEK1 ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C, D](#fig1s1){ref-type="fig"}), and the main text has been modified accordingly (subsection "MEK1 is required for cell competence to differentiate").

2\) Since it could be done with simple qRT-PCR, it seems important to know whether the Ventx2 morpholino influences the expression of any of the other Ventx genes?

We have performed this analysis, and present the corresponding results in [Figure 4---figure supplement 1B, C](#fig4s1){ref-type="fig"}. By RT-qPCR, we observed that *ventx1* and *ventx3*, as well as *pou5f3.1* and *pou5f3.2* expression is lower in Ventx2 morphant embryos at gastrula stage, compared to uninjected control embryos. Conversely, the pro-differentiation marker *gsc*, which is a known negative target of Ventx2 (Sander V et al., 2007; Trindade M et al., 1999), was up-regulated. The same conclusion was obtained through whole-mount in situ hybridization of *ventx1* and *gsc*. We conclude that Ventx2 knockdown leads to a global decrease of Ventx gene expression, and probably activity. This new information is now mentioned in the main text (subsection "Ventx2 inhibition by MEK1 is required for embryonic cell commitment").

3\) Rather than argue the point, the authors should repeat the study on GSK3-MEK interaction as previously suggested (\"In fact the authors should check whether the MEK regulated activity they observe is GSK3-dependent.\"), as it would both solidify previous conclusions and help define the mechanism reported here.

To address whether GSK3 is involved in the MEK1-dependent phenomenon that we have uncovered, we used a dominant-negative version of GSK3, which has been very well characterized in *Xenopus*. The rationale is that if GSK3 and MEK1 collaborate to control pluripotency in *Xenopus* embryos, dnGSK3 should cause similar effects as Mk-MO. First, we verified in a classical assay that dn-GSK3 RNA injection could efficiently induce secondary body axis formation. As expected, RT-qPCR analysis revealed that dn-GSK3 strongly up-regulated the expression of the organizer genes siamois and *gsc* at the early gastrula stage. In contrast, dnGSK3 significantly down-regulated the expression of all *ventx* and *pou5f3* genes in the same embryos. Whole-mount in situ hybridization confirmed that *ventx2* and *pou5f3.2* were down-regulated, whereas *gsc* was up-regulated in embryos injected with dn-GSK3. Thus, MEK1 and GSK3 knockdown had opposite effects on the level of expression of pluripotency regulators. Finally, immunofluorescence analysis revealed that dn-GSK3 did not induce Ventx2-Myc protein stabilization, unlike Mk-MO. This observation is consistent with the data of Zhu et al., (2002), which indicated that GSK3 was not required for Ventx2 proteolysis. Furthermore, Ventx proteins were not recovered in genome-wide GSK3-dependent proteomes (see GSK3 PROTEOME TABLE1 and TABLE2 in <http://www.hhmi.ucla.edu/derobertis/>; or Acebron S et al., 2014 NCBI GEO accession numbers GSE50629 and GSE50248). We conclude that GSK3 is likely not involved in the transition from pluripotency to commitment of embryonic cells, which primarily involves MEK1-dependent destabilization of the pluripotency regulatory network. These results are presented in the new [Supplementary file 1](#SD3-data){ref-type="supplementary-material"} and mentioned in the Discussion section of the main text (second paragraph).

4\) As previously suggested, please test the hypothesis by depleting MEK from animal caps and/or embryos and look at ability of BMP, Activin or Wnt to induce any lineages), would address my concerns about whole embryos versus animal caps. In this case, qRT-PCR of a few diagnostic markers (rather than RNA SEQ or microarray analyses) should be sufficient.

As requested, we tested whether animal caps responded to inducers of differentiation in absence of MEK1 activity. We used BMP4, NOGGIN, a low dose of NODAL, and a high dose of NODAL recombinant proteins to induce epidermal, neural, mesodermal and endodermal fates, respectively. We did not use Wnt, as it is known to be a rather poor germ-layer inducer in animal caps. Similar to our initial observations in whole embryos, none of the inducers tested could activate differentiation markers in Mk morphant animal caps, as revealed by RT-qPCR analysis. This analysis confirmed our initial conclusion that MEK1 activity is required for embryonic cell competence to respond to inducers of differentiation. These new results have been included in [Figure 2B](#fig2){ref-type="fig"}, and are described in the main text (subsection "MEK1 is required for cell competence to differentiate").
